As more innovative drugs emerge for various forms of neuromuscular disease, the Food and Drug Administration is under increasing pressure to approve the treatments. Patients are understandably clamoring for cures, and the increasing demands from families have prompted lawmakers to scrutinize agency initiatives. Signs of the growing pressure were evident two years ago in the ruckus over the FDA’s approval of a medicine for Duchenne muscular dystrophy. Meanwhile, these treatments are being launched at increasingly high price points. On the eve of a Muscular Dystrophy Association conference, we spoke briefly with Dr. Janet Woodcock, who heads the Center for New Drug Evaluation and Research at the FDA, about agency moves to hasten approvals. This is an edited version of the conversation…

Pharmalot: In your view, how far have we come recently?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy